JP2021500406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500406A5 JP2021500406A5 JP2020543406A JP2020543406A JP2021500406A5 JP 2021500406 A5 JP2021500406 A5 JP 2021500406A5 JP 2020543406 A JP2020543406 A JP 2020543406A JP 2020543406 A JP2020543406 A JP 2020543406A JP 2021500406 A5 JP2021500406 A5 JP 2021500406A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- cancer
- tumor
- specific
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008874 T cell receptors Proteins 0.000 claims description 70
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 210000001728 clone cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717578.7A GB201717578D0 (en) | 2017-10-26 | 2017-10-26 | Novel T-cell receptor |
| GB1717578.7 | 2017-10-26 | ||
| GBGB1806155.6A GB201806155D0 (en) | 2017-10-26 | 2018-04-16 | Novel t-cell receptor |
| GB1806155.6 | 2018-04-16 | ||
| PCT/GB2018/053045 WO2019081902A1 (en) | 2017-10-26 | 2018-10-22 | NEW LYMPHOCYTE RECEPTOR T |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500406A JP2021500406A (ja) | 2021-01-07 |
| JP2021500406A5 true JP2021500406A5 (enExample) | 2021-11-25 |
| JP7289311B2 JP7289311B2 (ja) | 2023-06-09 |
Family
ID=60580240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543406A Active JP7289311B2 (ja) | 2017-10-26 | 2018-10-22 | 新規ｔ細胞受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11725039B2 (enExample) |
| EP (2) | EP3700925B8 (enExample) |
| JP (1) | JP7289311B2 (enExample) |
| KR (1) | KR20200078497A (enExample) |
| CN (1) | CN111278855B (enExample) |
| AU (2) | AU2018356944A1 (enExample) |
| BR (1) | BR112020007880A2 (enExample) |
| CA (1) | CA3077635A1 (enExample) |
| DK (1) | DK3700925T3 (enExample) |
| EA (1) | EA202091015A1 (enExample) |
| ES (1) | ES2907819T3 (enExample) |
| GB (2) | GB201717578D0 (enExample) |
| IL (1) | IL274025A (enExample) |
| MX (1) | MX2020004334A (enExample) |
| PL (1) | PL3700925T3 (enExample) |
| SG (1) | SG11202002537WA (enExample) |
| WO (1) | WO2019081902A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
| KR20220147583A (ko) * | 2020-01-09 | 2022-11-03 | 바이오뮤넥스 파마슈티컬스 | Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체 |
| JP7680769B2 (ja) * | 2020-01-16 | 2025-05-21 | ウニヴェルズィテート バーゼル | 免疫調節用のｍｒ１リガンド及び医薬組成物 |
| WO2021250511A1 (ko) * | 2020-06-10 | 2021-12-16 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
| IL302481A (en) * | 2020-11-04 | 2023-06-01 | Fate Therapeutics Inc | Multiplexed engineered ipsc and immune effector cells targeting solid tumors |
| WO2022118043A1 (en) | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
| WO2022248881A1 (en) | 2021-05-28 | 2022-12-01 | Enara Bio Limited | Novel protein-ligand complex |
| WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023002204A1 (en) | 2021-07-21 | 2023-01-26 | Enara Bio Limited | T-cell receptor |
| KR20230088292A (ko) * | 2021-12-10 | 2023-06-19 | 주식회사 유틸렉스 | MR1 제한적 Panck T 세포 및 이의 제조방법 |
| EP4472742A1 (en) | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| IL316032A (en) | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| CN106103711A (zh) | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| CA3054758A1 (en) * | 2017-03-07 | 2018-09-13 | Universitat Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
-
2017
- 2017-10-26 GB GBGB1717578.7A patent/GB201717578D0/en not_active Ceased
-
2018
- 2018-04-16 GB GBGB1806155.6A patent/GB201806155D0/en not_active Ceased
- 2018-10-22 EP EP18795783.2A patent/EP3700925B8/en active Active
- 2018-10-22 KR KR1020207011102A patent/KR20200078497A/ko not_active Ceased
- 2018-10-22 DK DK18795783.2T patent/DK3700925T3/da active
- 2018-10-22 CN CN201880069546.9A patent/CN111278855B/zh not_active Expired - Fee Related
- 2018-10-22 SG SG11202002537WA patent/SG11202002537WA/en unknown
- 2018-10-22 AU AU2018356944A patent/AU2018356944A1/en not_active Abandoned
- 2018-10-22 ES ES18795783T patent/ES2907819T3/es active Active
- 2018-10-22 EP EP21214567.6A patent/EP4039700A1/en not_active Withdrawn
- 2018-10-22 CA CA3077635A patent/CA3077635A1/en active Pending
- 2018-10-22 BR BR112020007880-8A patent/BR112020007880A2/pt unknown
- 2018-10-22 PL PL18795783T patent/PL3700925T3/pl unknown
- 2018-10-22 JP JP2020543406A patent/JP7289311B2/ja active Active
- 2018-10-22 WO PCT/GB2018/053045 patent/WO2019081902A1/en not_active Ceased
- 2018-10-22 EA EA202091015A patent/EA202091015A1/ru unknown
- 2018-10-22 MX MX2020004334A patent/MX2020004334A/es unknown
-
2020
- 2020-04-19 IL IL274025A patent/IL274025A/en unknown
- 2020-04-24 US US16/858,082 patent/US11725039B2/en active Active
-
2021
- 2021-01-20 US US17/153,329 patent/US11078252B2/en active Active
-
2024
- 2024-04-26 AU AU2024202735A patent/AU2024202735A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500406A5 (enExample) | ||
| CN109219445B (zh) | 嵌合抗原受体修饰细胞治疗癌症的应用 | |
| JP6970974B2 (ja) | 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ | |
| JP2021058197A5 (enExample) | ||
| TWI803835B (zh) | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 | |
| JP2019536430A5 (enExample) | ||
| CN115551537A (zh) | 肿瘤细胞疫苗 | |
| JP2017537622A5 (enExample) | ||
| JP2021505190A5 (enExample) | ||
| JP2021501567A5 (enExample) | ||
| JPWO2020193767A5 (enExample) | ||
| JPWO2020048995A5 (enExample) | ||
| JPWO2021030149A5 (enExample) | ||
| CN113038939A (zh) | 损害内施用pd-1抑制剂用于治疗皮肤癌 | |
| KR102624844B1 (ko) | 암의 향상된 치료 | |
| Gudi et al. | Preliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers | |
| JPWO2022109611A5 (enExample) | ||
| JPWO2020087116A5 (enExample) | ||
| de Sostoa Pomés et al. | Targeting the tumor stroma with a bispecific T-cell engager-armed oncolytic adenovirus | |
| EP4337763A1 (en) | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases | |
| CN120590509A (zh) | 分离的特异性结合MHC/Survivin表位复合体的肿瘤特异性TCR及其用途 | |
| CN119486753A (zh) | 个体化癌症表位及其使用方法 | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| Slingluff Jr | Immunology of Cancer |